#VRCI In Nov’23, expert organ transplant diagnostics firm Verici Dx (Mrkcap £16m) signed a ground breaking global licensing deal with Thermo Fisher Scientific ($215bn Mrkcap) to exclusively develop an assay for pre-transplant kidney testing. #TMO’s assay is to be based directly on #VRCI’s patented Clarava blood test that allows doctors to identify those patients (pre graft) most likely to require increased monitoring (post operation)- including adjustments to the type, dose & duration of immunosuppressants. Elsewhere, the agreement also granted Thermo Fisher Scientific the sole right (but not obligation) to manufacture, distribute & sell the prognostic worldwide. Alongside providing it with access to a portion of #VRCI’s proprietary urine samples – further highlighting the value stored within its treasure trove of research assets. In return Verici Dx received an upfront fee, augmented by staged payments dependent on operational deliverables (eg tech transfer & publications). Which in aggregate (assuming things go to plan) should equate to c.$5m by Nov24 with further instalments & ongoing royalties thereafter. Today #VRCI said it had “completed successful transfer of a portion of the urine samples” and “full payment had been received”. Meaning this alongside the Jan’24 $6.5m fund raise, should extend the group's cash run-way into 2026. CEO Sara Barrington adding: "We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in Verici Dx's data and sample assets for research purposes." Looking ahead, Singer Capital Markets have a target price of 20p/share and are forecasting sales to jump to $7.5m and $13.0m this year and next (vs $1.0m LY), with #VRCI also becoming profitable in 2025 ($1.3m EBITDA). Disclosure: Verici Dx are a Vox Markets client
Paul Hill’s Post
More Relevant Posts
-
Gillies McIndoe wins Best Licensing Deal at KCA Awards for keloid treatment The Gillies McIndoe Research Institute, in collaboration with AFT Pharmaceuticals and Massey Ventures, has won the prestigious Best Licensing Deal award at the 2024 Knowledge Commercialisation Australasia (KCA) Awards. The recognition follows last year's award for their work on Strawberry Birthmark treatments and highlights a breakthrough in early-stage licensing for a promising new keloid scar therapy. With the lab work being worked on by Gillies McIndoe's postdoctoral researcher Dr Alex Chan, this innovative project aims to address the underlying causes of keloid and fibrotic conditions — marked by excessive collagen production that leads to raised, often painful scars beyond the original injury site. With limited current treatment options for keloids and frequent recurrence after intervention, the research focuses on targeting specific molecular pathways to improve patient outcomes. #gilliesmcindoe #keloidresearch #scartherapy #innovationinhealthcare #KCAs2024 #AFTPharmaceuticals #MasseyVentures #collaborativeresearch #medicalbreakthrough #fibroticconditions #healthcareinnovation #scarresearch #collagentherapy #awardwinningresearch #knowledgecommercialisation #iranzresearch https://lnkd.in/gfA7bxd3
-
Focused Ultrasound for Chronic Pain and Depression: Recently published clinical trial results have added further evidence to support the safety and efficacy of SPIRE Therapeutics neuromodulation device, DIADEM. The company’s device uses low-intensity focused ultrasound (LIFU) to stimulate and treat the areas of the brain affected by chronic pain and depression. #FocusedUltrasound #Neuromodulation #ClinicalTrial Access the publications and learn more about the company and its technology: https://ow.ly/1wGT50U9otF
-
-
New featured CE! 🔗 https://bit.ly/4e8RVmL The blood-brain barrier (BBB) remains a significant blockade for effective drug delivery in treating diffuse intrinsic pontine glioma (DIPG). Low-frequency focused ultrasound (FUS) therapy in conjunction with intravenous microbubbles can transiently disrupt the BBB in a localized manner to facilitate drug delivery. This review examines recent preclinical studies evaluating the safety and feasibility of FUS-mediated BBB opening in the brainstem. #CME #MedEd #RadEd
-
-
Important new milestone for #Novadip's NVDX3 securing IND approval from the FDA to initiate a phase 2b/3 study in cervical spine fusion. Built upon robust preclinical and clinical datasets, NVDX3 has potential to replace existing allogenic bone grafting materials – providing patients with complex comorbidities better bone fusion success. "The trial will accelerate our capability to bring NVDX3 to patients with complex needs, providing them with a better chance of healing compared to standard-of-care treatments. These strategic steps enable us to take NVDX3 to the next level,” said Denis Dufrane, MD, PhD, CEO of NOVADIP Biosciences S.A. 👉 Read the full release: https://lnkd.in/dUHwjR2F
-
-
📣 New publication alert!📣 We're delighted that our paper with innoVitro has been published: "Chamber-Specific Contractile Responses of Atrial and Ventricular hiPSC Cardiomyocytes to GPCR and Ion Channel Targeting Compounds: A Microphysiological System for Cardiac Drug Development". Human iPSC technology has been used to produce more human-relevant models for cardiac research and cardiotoxicity screening. But given the chamber-specific nature of certain conditions (for example, atrial fibrillation versus hypertrophic cardiomyopathy) these models must incorporate chamber types specific to the application. In collaboration with innoVitro, we sought to explore the chamber-specific pharmacology of axoCells™ atrial and ventricular cardiomyocytes on an innovative platform combining Nanion technologies' FLEXcyte 96 contractility platform with innoVitro's FLEXcyte plates. Our results demonstrated key pharmacological differences between axoCells atrial and ventricular cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling. Click here to read the paper: https://hubs.la/Q02D8_z-0 #iPSCs #cardiomyocytes #CiPA #cardiotoxicity #StemCells
-
-
📣 New publication alert!📣 We're delighted that our paper with innoVitro has been published: "Chamber-Specific Contractile Responses of Atrial and Ventricular hiPSC Cardiomyocytes to GPCR and Ion Channel Targeting Compounds: A Microphysiological System for Cardiac Drug Development". Human iPSC technology has been used to produce more human-relevant models for cardiac research and cardiotoxicity screening. But given the chamber-specific nature of certain conditions (for example, atrial fibrillation versus hypertrophic cardiomyopathy) these models must incorporate chamber types specific to the application. In collaboration with innoVitro, we sought to explore the chamber-specific pharmacology of axoCells™ atrial and ventricular cardiomyocytes on an innovative platform combining Nanion technologies' FLEXcyte 96 contractility platform with innoVitro's FLEXcyte plates. Our results demonstrated key pharmacological differences between axoCells atrial and ventricular cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling. Click here to read the paper: https://hubs.la/Q02D930Y0 #iPSCs #cardiomyocytes #CiPA #cardiotoxicity #StemCells
-
-
Ophthopedia Update:Impact of a Recall of Intravitreal Bevacizumab: A HALO Registry Review: Intravitreal use of bevacizumab (IVB) was first reported nearly two decades ago for neovascular age-related macular degeneration (nAMD).1 Subsequently, IVB was shown to be non-inferior to ranibizumab for the treatment of nAMD in a large randomized clinical trial.2 Since then, the use of IVB has been widespread across retinal pathologies. #Ophthalmology #Retina #Ophthotwitter
Impact of a Recall of Intravitreal Bevacizumab: A HALO Registry Review
ophthalmologyretina.org
-
We started a longitudinal study to assess imaging biomarkers in relation to new bone formation and inflammatory characteristics in patients with axial spondyloarthritis and psoriatic arthritis together with COPECARE and the department of radiology of Herlev og Gentofte Hospital. Earlier studies (Refs: Willesen ST, et al. Ann Rheum Dis 2024; Jans LBO, et al. Radiology 2022) demonstrated the ability of #BoneMRI to detect structural changes in these populations, however this study investigates the effect of treatment with a pharmaceutical compound and the ability to detect structural bone changes in an early phase. Paper: https://lnkd.in/e9FkQxJs Willesen ST, et al. Ann Rheum Dis 2024. Simone Tromborg Willesen Mikkel Østergaard Rigshospitalet #BoneMRI #Spondyloarthritis #EarlyDetection #MRI
-
-
🧪 PBMC processing is operator and time sensitive and requires consistency every time. At hLAB, our scientists have been qualified by top 10 pharma companies to process PMBCs in accordance with their specific isolation methodologies. This, in combination with our cryopreservation services, allows us to effectively tech transfer while ensuring sample integrity and consistency across studies. To learn more about our PBMC isolation and storage capabilities, visit https://lnkd.in/eszX5Xr5 #hLAB #PBMC #ClinicalResearch #Virology #InfectiousDiseases
-
PolyActiva is pleased to announce it has been awarded a $1.5m CUREator Grant, made available through the Federal Government’s Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) funding. With this funding, PolyActiva will complete a Phase 1 clinical trial in Australia of PA5346, its second-generation latanoprost-releasing ocular implant designed to deliver 12 months of treatment for patients with glaucoma. PolyActiva’s unique and differentiated Prezia™ drug delivery platform is used to develop injectable ocular implants to treat various ophthalmic conditions. PolyActiva’s first-generation lead product (PA5108) is demonstrating promising results in phase 2 clinical trials targeting 6 months of therapy. PolyActiva’s second-generation product, PA5346, is a small biodegradable rod that is expected to deliver a sustained daily dose of latanoprost to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension over 12 months. “We are delighted to be the recipient of a CUREator Grant for the development of PA5346, which provides us with the opportunity to pursue development of a second clinical candidate in our pipeline of glaucoma treatments. Early data with PA5346 suggests it has the potential to provide 12 months treatment for patients with glaucoma. The CUREator Grant will allow us to determine if this product truly meets that objective” says Vanessa Waddell, CEO of PolyActiva. “Because PolyActiva’s implants rapidly biodegrade at the end of the treatment period, we believe that they will be able to be given repeatedly, and that would change the way we manage this eye disease.” Read the full statement here: https://lnkd.in/emSYKvkT #Glaucoma #DrugDelivery #CUREator #Biotechnology #Innovation
-
Knowledge is knowing that a tomato is a fruit. Wisdom is knowing not to put it in a fruit salad
6moOnce placing / raise shares are churned through it could get interesting! 🤔